Home/Pipeline/GPR75 Program

GPR75 Program

Obesity

PreclinicalActive

Key Facts

Indication

Obesity

Phase

Preclinical

Status

Active

Company

Orion Biotechnology

About Orion Biotechnology

Orion Biotechnology is a preclinical-stage biotech company developing first-in-class GPCR-targeted therapies for obesity and metabolic diseases. Its core asset is the PROcisionX™ platform, which integrates phage display, multiplex chemical synthesis, and structure-activity analysis to generate optimized drug candidates in under six months. The company is advancing two lead candidates against the novel target GPR75 towards clinical development, led by a seasoned management team with deep pharmaceutical industry experience.

View full company profile

Therapeutic Areas

Obesity Metabolic Disorders

Other Obesity Drugs

Drug	Company	Phase	Status
LET003	Harbour BioMed	Discovery	Active (Global)
LET001	Harbour BioMed	Discovery	Active (Global)
Obesity Target Discovery Collaboration	Fauna Bio	Target Discovery/Preclinical	Active
GLP-1 variants	Heligenics	Discovery	Active
MYO Platform (Metabolic Disease)	Renbio	Pre-clinical	Active
Obesity Clinical Trials	IMA Clinical Research	Not Applicable (Service)	Active
KAYO-2000	KayoThera	Preclinical	Active
MVD-1 (SANA)	Eolo Pharma	Phase 1	Active
GIP-neutralizing antibody	Helicore Biopharma	Pre-clinical	Active
Antral Gastroplasty / Endoscopic Sleeve	Endo-TAGSS	Pre-clinical	Active
Undisclosed siRNA Programs	Moonwalk Biosciences	Pre-clinical	Active
VIAL-INHBE (siRNA)	VIAL Dermatology CRO	Phase 1	Active